Back to search
FDAFDA · Food and drugs·Recall number Z-0001-2027

HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic

Published October 21, 2026 · Recall initiated: September 3, 2026

Summary

FDA records medical device Class I recall Z-0001-2027, published October 21, 2026 and initiated September 3, 2026. Recalling firm: Instrumentation Laboratory; Status: Ongoing; Reported quantity: 434 units; Lot: Part Number: 0009800127. UDI-DI: 08426951126545. Lot Number (Expiration Date): B40005 (01/16/2027), B38062 (11/01/2026). Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Potential for invalid calibration curve or negative mean bias of up to 47% with patient samples.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Instrumentation Laboratory
Distributor
Worldwide - US Nationwide distribution in the states of AR, AZ, CA, CT, FL, GA, MA, MD, NJ, NY, PA, RI, TN, WA, WV and the countries of Austria, Belgium, Switzerland, Costa Rica, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, India, Italy, Jordan, Japan, South Korea, Luxembourg, Latvia, Netherlands, Saudi Arabia, Sweden, Singapore.
Lot
Part Number: 0009800127. UDI-DI: 08426951126545. Lot Number (Expiration Date): B40005 (01/16/2027), B38062 (11/01/2026).
Risk classification
Class I
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was HemoslL AcuStar HIT-lgG(PF-4). Part Number: 0009800127. in vitro diagnostic recalled?

Yes. FDA published recall Z-0001-2027 on October 21, 2026. Reported hazard: Potential for invalid calibration curve or negative mean bias of up to 47% with patient samples.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit